Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Lung Neoplasms 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ductal, Breast 2Adenocarcinoma Of Esophagus 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1The Neoadjuvant Therapy 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Seminoma 1Recurrence 1Primary Malignant Neoplasm of Ovary 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1

Interventions

Triptorelin Pamoate 1Paclitaxel 1Fulvestrant 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × The Neoadjuvant Therapy × Paclitaxel × Clear all
NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡